-+ 0.00%
-+ 0.00%
-+ 0.00%

Jaguar Health says two late-breaking pediatric intestinal failure crofelemer abstracts accepted at ESPGHAN

PUBT·04/24/2026 12:32:30
Listen to the news
Jaguar Health says two late-breaking pediatric intestinal failure crofelemer abstracts accepted at ESPGHAN
  • Jaguar Health reported acceptance of two late-breaking abstracts on liquid oral crofelemer as adjunctive therapy for pediatric intestinal failure due to microvillus inclusion disease (MVID) or short bowel syndrome (SBS).
  • Results will be presented at European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) 58th annual meeting.
  • Investigator-initiated pediatric studies indicated crofelemer was well tolerated, supported growth, reduced reliance on parenteral support.
  • Jaguar said enrollment is complete in ongoing randomized trial in pediatric MVID, targeting NDA filing in mid-2027.
  • Napo Therapeutics continued enrolling adults with SBS-related intestinal failure in randomized double-blind placebo-controlled trial in Germany, Italy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604240830ACCESSWRNAPR_____1160834) on April 24, 2026, and is solely responsible for the information contained therein.